Proteomics has the capacity to explain questions that were unsolved by genomics, as proteins are the functional unit of cells. Advancements in the technology of mass spectrometry, chromatography and development of computer algorithms for database searching facilitates the proteomics research.‐ She further adds that ‐the analysis of target proteins for disease diagnosis is the largest application of proteomics.
Global Proteomics Market was valued at $17,988 million in 2015, and is expected to reach $44,452 million by 2022, supported by a CAGR of 13.7%. Proteomics is the study of the structure and functions of proteins that can be used in the drug discovery, diagnosis, and treatment of diseases. A proteome is never constant as it differs from one cell to other with time.
The key drivers of the market include increased R&D funding by leading players and government agencies, such as National Institutes of Health (NIH) and National Science Foundation (NSF), and technological advancements, such as development of dual mass analyzers (for instance LC/MS, GC/MS, FT-MS, and MALDI-TOF/TOF) and improvements in the liquid chromatography & gel electrophoresis procedures. Also, the increase in popularity of personalized medicines is set to propel the market. However, high cost of the instruments and dearth of skilled researchers hamper the market growth.
Get the PDF brochure of this market study@ https://www.alliedmarketresearch.com/request-sample/1677
Proteomics is used to evaluate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. In addition, it finds extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis, which has led to the stellar growth of the proteomics market in the past few years. With the increase in awareness regarding the benefits of personalized medicines, companies and government organizations have increased their R&D expenditure on the development of proteomics. As per the proteomics market research report, it is estimated that reagents segment will continue to lead the overall market during the forecast period.
Increasing R&D expenditure to drive the proteomics market size
Large number of organizations invest in the R&D of proteomics to understand the metabolic pathway involved in the progression of disease and the development of novel molecules for its treatment and diagnosis. In addition, organizations such as National Institutes of Health (NIH) and National Science Foundation (NSF) raise funds for various proteomics projects. For instance, in September 2016, NIH announced to fund research on “Proteomics, Immunoassay for TB Activation in HIV Patients”. In 2015, National Cancer Institute offered grants for Clinical Proteomic Tumor Analysis Consortium (CPTAC) program. The governments of European countries also take various initiatives to promote proteomics research. The European Union’s Seventh Framework Programme supports proteomics research by funding a group of proteomics researchers from European institutes for the next four years. In Australia, with assistance from government funding, the R&D expenditure on proteomics is expected to increase by 58% in 2016.
Do Purchase Inquiry@ https://www.alliedmarketresearch.com/purchase-enquiry/1677
Technological advancements to drive the proteomics market
The recent technological advancements in the field of proteomics is expected to spur the proteomics market. These advancements attract the interest of pharmaceutical & biotechnology companies to venture in the field of proteomics as the convenience of use of the instrument and the outcome of the procedure have improved. For instance, technological advancements such as increased resolution of mass spectrometry helps to extract more information from minimal amount of sample. Similarly, dual mass analyzers such as LC/MS, GC/MS, FT-MS, and MALDI-TOF/TOF help to provide more detailed information about protein structure. Moreover, the development of improved liquid chromatography and gel electrophoresis have significantly helped in the protein identification and separation methods. Two-dimensional gel electrophoresis, which is based on isoelectric focusing (IEF) and denaturing polyacrylamide gel matrix for protein separation, have also been developed by scientist recently. These technological advancements are expected to propel the proteomics market.
Proteomics help to bridge the gap between the understanding of genome expression and cellular behavior
Proteomics enables the study of proteomes (the entire complement of proteins that is or can be expressed by a cell, tissue, or organism) as well as their interactions. Moreover, it characterizes protein expression profiles and identifies protein structures, localizations, activities, modifications, and interactions in physiological or pathological states. As proteins perform most biological functions, proteomics bridges the gap between the information coded in the genome sequence and cellular behavior. For instance, hepatocellular carcinoma is the third leading cause of death globalwide. Chemotherapeutic treatment is ineffective against hepatocellular carcinoma (HCC); hence, surgical removal or liver transplantation is the only treatment possible. Proteomics studies of HCC may decode the mechanisms of HCC initiation and progression, and it also has the potential to discover novel diagnostic biomarkers and therapeutic targets.
North America held the largest share of about two-fifth of the market in 2015. The increase in popularity and adoption of personalized medicines and favorable government funding and initiatives are the key factors that drive the market growth in this region. However, Asia-Pacific is expected to grow at a CAGR of 17.0% from 2016 to 2022. The rise in prevalence of chronic diseases and increase in interest of researchers to utilize proteomics in the disease diagnosis and treatment are expected to fuel the market growth.
Key players profiled in this report include Thermo Fisher Scientific Corporation, Agilent Technologies, Luminex Corporation, Danaher Corporation, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Waters Corporation, Caprion Proteomics, Inc., PerkinElmer, Inc., and Bruker Corporation.